The global Multiple System Atrophy (MSA) Therapeutics Market is currently valued at USD 137.3 Million in 2023 and is anticipated to expand at a CAGR of 4.4%. Owing to the technological advances in healthcare the market is likely to propel to USD 211.1 Million by 2033.
Rapidly growing geriatric population, promising pipeline drugs, and new product launches are likely to drive the growth of the multiple system atrophy (MSA) therapeutics Market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 137.3Million |
| Projected Forecast Value (2033) | USD 211.1 Million |
| Global Growth Rate (2023 to 2033) | 4.4% CAGR |
Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.
The slowness of movement, tremors, rigidity, and incoordination are the first signs and multiple system atrophy symptoms. The parkinsonian type (MSA-P) with primary symptoms similar to Parkinson's disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia is the most prominent multiple system atrophy symptoms of evaluation.
Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson's disease. Autonomic testing (such as blood pressure control and heart rate control), assessment of bladder function, and neuroimaging such as an MRI (magnetic resonance imaging) or PET scan are examples of diagnostic tests.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Multiple System Atrophy (MSA) Market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 4.4% in the above-mentioned forecast period.
The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for multiple system atrophy (MSA) therapeutics. The epidemic has had a direct influence on the supply and demand of medications, as well as on businesses and financial markets. It has also disturbed the distribution system.
The global multiple system atrophy (MSA) therapeutics markets grew at a CAGR of 4.0% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
The multiple system atrophy market share is expected to grow significantly, mainly due to increasing cases of neurodegenerative disorders. The multiple system atrophy market is expected to witness advancement in the upcoming years due to a new type of drug launch. Due to patent protection loss, new players are expected to enter the multiple system atrophy during the forecast years.
Increase in the Frequency of Neurodegenerative Diseases, Which Is One of the Primary Reasons Driving the Growth Market
The major market growth factors include the rising prevalence of neurodegenerative disorders, increasing awareness among the global population, and a strong product pipeline for neurological disease treatment. With the increasing global population and an average lifespan, the prevalence of multiple system atrophy is on the rise.
People affected by MSA experience dysfunction of the autonomic nervous system, which commonly manifests as orthostatic hypotension, impotence, loss of sweating, dry mouth and urinary retention, and incontinence.
According to the National Library of Medicine - MSA is considered an orphan disease with an annual incidence rate of 0.1-3 per 100,000 depending on age and geographic region.
Increase in government support and drug approval to widen the market scope.
In addition, increasing government support and increasing awareness about neurodegenerative disorders fuel the market growth. The rise in expenditure on healthcare in developing countries and the growth in patient awareness of the use of nerve monitoring devices provide new opportunities for market players. Awareness regarding the clinical benefits of nerve monitoring drives the sales of multiple system atrophy therapeutics market in the forecasting period.
For instance, in September 2020 - Alterity Therapeutics biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases announced the approval of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The approval of this IND authorizes Alterity to conduct its Phase 2 clinical trial in the USA.
Principal Consultant
Inadequate reimbursement policies may hamper global market growth.
The lack of government and hospital reimbursement policies for treating neurodegenerative illnesses such as Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease restricts the market growth. On the other hand, patients are switching to generics due to the lower cost, which is expected to limit the use of patented drugs.
The exceptionally high price is expected to stifle market growth by limiting access to quality treatment in middle and low-income countries.
High failure rates in clinical trials and research & development (R&D): Clinical trial and research and development (R&D) failure rates have always been a significant challenge within the multiple system atrophy therapeutics market. Companies are constantly investing in Research and Development to develop treatment options for neurodegenerative diseases, but very few treatments are currently approved.
Growing Prevalence of MSA in Region to Drive the Market Growth
North America accounts for the market share of 45.3% of multiple system atrophy therapeutics in 2023 and is likely to lead the multiple system atrophy market during the forecast period.
Growing medication demand, high prices, increased Research and Development investment, and favorable health reimbursement policies are driving the growth of the multiple system atrophy market in North America.
MSA is affecting potentially 15,000 to 50,000 Americans, including men and women and all racial groups. Symptoms of the disease appear in a person’s 50s and advance rapidly over the course of 5 to 10 years, with progressive loss of motor function and eventual confinement to bed. People with MSA often develop pneumonia in the later stages of the disease and may suddenly die from cardiac or respiratory issues.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increased R&D Investment and Favourable Health Reimbursement Policies are Driving The Growth of The Market In Europe
Europe is expected to be the most significant neurodegenerative disease market. Factors affecting the growth of the market studied are the increasing number of MSA disorders, and research and development by private and government organizations focused on developing treatments for such diseases.
The growth of the European multiple system atrophy therapeutics market during the forecast period is attributed to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government. Europe to exhibit a CAGR of 4.2% in the multiple system atrophy therapeutics market during the forecast period.
For instance, in August 2022, Alterity Therapeutics a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.
| UK | 4.2% |
|---|---|
| India | 3.8% |
| South Korea | 4.0% |
| China | 4.1% |
| USA | 4.4% |
PET Scan Segment remains dominant among other types
Based on diagnosis multiple system atrophy market is segmented into Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others. Among these, the PET scan segment dominated the market in 2023 with a revenue share of 34.6%.
A PET scan (positron emission tomography, which allows doctors to see how organs and tissues are functioning) is sometimes used to see if the metabolic function is reduced in specific parts of the brain. DaTscan can assess the dopamine transporter in a part of the brain called the striatum and can help physicians determine if the condition is caused by a dopamine system disorder; however, this test cannot differentiate between MSA and Parkinson’s disease. Individuals with MSA typically do not have sustained improvement in their symptoms with levodopa (a drug used to treat Parkinson’s disease), a finding that often supports the diagnosis of MSA.
How do New Entrants Contribute to the Multiple System Atrophy (MSA Therapeutics Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the multiple system atrophy therapeutics market.
Some of the start-ups in the multiple system atrophy therapeutics market include-
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | USD 137.3 Million |
| Projected Forecast Value (2033) | USD 211.1 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Type, Diagnosis, Regions |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC, South Africa, Israel |
| Key Companies Profiled | Biohaven Pharmaceuticals, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; AstraZeneca plc; Theravance Biopharma, Inc.; Merck & Co.; Neuropore Therapies Inc; Newron Pharmaceuticals SpA; ProMIS Neurosciences Inc; Stealth BioTherapeutics Corp; Chelsea Therapeutics International, Ltd. |
| Customization | Available Upon Request |
The global multiple system atrophy therapeutics market is likely to reach a valuation of USD 137.3 Million by the end of 2023.
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., and Merck & Co are some of the key players in the global multiple system atrophy therapeutics market.
Sales of the multiple system atrophy therapeutics market are likely to expand at 4.4% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the multiple system atrophy therapeutics market.
By the end of 2033, the global market for multiple system atrophy therapeutics market is predicted to reach a valuation of USD 211.1 Million
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Parkinsonian 5.2. Cerebellar 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Magnetic Resonance Imaging (MRI) 6.2. Positron Emission Tomography (PET) 6.3. Single Photon Emission Computed Tomography (SPECT) 6.4. Tilt Table Test 6.5. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. Middle East & Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Biohaven Pharmaceuticals, Inc. 17.2. Sumitomo Dainippon Pharma Co., Ltd. 17.3. AstraZeneca plc 17.4. Theravance Biopharma, Inc. 17.5. Merck & Co. 17.6. Neuropore Therapies Inc 17.7. Newron Pharmaceuticals SpA 17.8. ProMIS Neurosciences Inc 17.9. Stealth BioTherapeutics Corp 17.10. Chelsea Therapeutics International, Ltd. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Multiple System Atrophy (MSA) Therapeutics Market
